-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Rym+HYmm9rbIJIckZ4605gZ7EvoGvS3o33xVB6so6E2SZCib2/LDAuuHS5s2eKZG
 Og6VEAUO8ukFDnPgiRt7fQ==

<SEC-DOCUMENT>0001178913-09-001020.txt : 20090506
<SEC-HEADER>0001178913-09-001020.hdr.sgml : 20090506
<ACCEPTANCE-DATETIME>20090506171748
ACCESSION NUMBER:		0001178913-09-001020
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090506
DATE AS OF CHANGE:		20090506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLURISTEM THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001158780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				980351734
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-151761
		FILM NUMBER:		09802473

	BUSINESS ADDRESS:	
		STREET 1:		MATAM ADVANCED TECHNOLOGY PARK
		STREET 2:		BUILDING NO. 20
		CITY:			HAIFA
		STATE:			L3
		ZIP:			31905
		BUSINESS PHONE:		972-4-850-1080

	MAIL ADDRESS:	
		STREET 1:		MATAM ADVANCED TECHNOLOGY PARK
		STREET 2:		BUILDING NO. 20
		CITY:			HAIFA
		STATE:			L3
		ZIP:			31905

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLURISTEM LIFE SYSTEMS INC
		DATE OF NAME CHANGE:	20030701

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AI SOFTWARE INC
		DATE OF NAME CHANGE:	20010906
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>zk96720.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\edgar filing\Pluristem Therapeutics Inc\96720\a96720.eep -->
     <!-- Control Number: 96720                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Pluristem Therapeutics Inc                                       -->
     <!-- Project Name:   424B5                                                            -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>424B5</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Filed Pursuant to Rule
424(b)(5) </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Right-TNR" FSL="Workstation" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Registration
No.&nbsp;333-151761</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<p ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>PROSPECTUS SUPPLEMENT
NO. 3</B>
<BR>(to prospectus dated July 1, 2008, as
previously supplemented <BR>by Prospectus Supplement No. 1 filed on August 6, 2008 and<BR>
Prospectus Supplement No. 2 filed on September 24, 2008) </FONT></P>


<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH></TH>
     <TH></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="70%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">888,406 shares of common stock<BR>
Warrants to purchase up to 488,623 shares of common stock<BR>
<BR>
Price per share: $1.50<BR>
Exercise price of warrants: $1.96 per share of common stock
</FONT></TD>
     <TD WIDTH="30%" align=right><IMG SRC="pluristem.jpg"></TD></TR>
</TABLE>
<BR>





<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pluristem Therapeutics Inc. is
offering for sale 888,406 shares of its common stock and warrants to purchase up to
488,623 shares of common stock pursuant to this prospectus supplement and related
prospectus attached hereto. We use the term, this Prospectus, to mean this prospectus
supplement and the accompanying prospectus, including the information incorporated by
reference herein. This Prospectus also covers the shares of common stock issuable upon
exercise of the warrants. Warrants may be purchased only together with shares of common
stock but may be subsequently transferred separately. A warrant to purchase 0.55 share of
common stock will be issued together with each share purchased. The shares and the
warrants are sometimes referred to as units. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The last reported sale price on the
Nasdaq Capital Market of our common stock on May 5, 2009 was $1.64 per share, and the
closing bid price was $1.62 per share. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock trading symbols:
 Nasdaq Capital Market: PSTI.  Frankfurt Stock Exchange: PJT. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>This investment involves a high
degree of risk.&nbsp; See &#147;Risk Factors&#148; beginning on page S-4, as well as the
section called &#147;Risk Factors&#148; beginning on page 12 of our Annual Report on Form
10-K for our 2008 fiscal year filed with the Securities and Exchange Commission and
incorporated by reference into the accompanying prospectus.</B> </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these
securities, or determined if this prospectus supplement or the accompanying prospectus is
truthful or complete.&nbsp; Any representation to the contrary is a criminal offense.</B> </FONT> </P>






<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1>Per Share</FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1>Per Warrant<BR>
Exercise Share</FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1>Total</FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1>&nbsp;</FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#cceeff">
     <TD WIDTH="57%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>Public offering price for shares</FONT></TD>
     <TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>  1. 50</FONT></TD>
        <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>-</FONT></TD>
        <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD WIDTH="9%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2> 1,332,610</FONT></TD>
        <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>Placement agency fees</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>6</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>%</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>         1.875</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>    79,957</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#cceeff">
     <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>Public offering price (exercise price) for warrant exercise shares</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>-</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>          1.96</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>   957,701</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>Total proceeds, before expenses, to Pluristem Therapeutics Inc. from both</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;shares and warrant exercise shares</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2></FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2></FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2> 2,290,311</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Delivery of the units will be made on
or about May 8, 2009.&nbsp; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Rodman &amp; Renshaw, LLC is acting
as placement agent in the offering of units. Because there is no minimum offering amount
required as a condition to closing in the offering of units, the placement agency fees and
net proceeds to us, if any, in this offering may be less than the offering amounts set
forth above. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Rodman &amp; Renshaw,
LLC </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The
date of this prospectus supplement is May 6, 2009. </FONT></P>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>TABLE OF CONTENTS </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PROSPECTUS SUPPLEMENT </FONT></P>


<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1>Page</FONT><HR WIDTH=95% SIZE=1 COLOR=black NOSHADE></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1>&nbsp;</FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TD WIDTH=90% ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></TD>
     <TD WIDTH=10% ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>S-3</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;THE OFFERING</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>S-3</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;RISK FACTORS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>S-4</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;USE OF PROCEEDS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>S-4</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;DILUTION</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>S-5</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;PLAN OF DISTRIBUTION</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>S-6</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;DESCRIPTION OF WARRANTS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>S-7</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;LEGAL MATTERS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>S-10</FONT></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PROSPECTUS </FONT></P>


<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1>Page</FONT><HR WIDTH=95% SIZE=1 COLOR=black NOSHADE></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1>&nbsp;</FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TD WIDTH=90% ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;ABOUT THIS PROSPECTUS</FONT></TD>
     <TD WIDTH=10% ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>2</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;OUR COMPANY</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>3</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;RISK FACTORS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>3</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>3</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;USE OF PROCEEDS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>4</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;THE SECURITIES WE MAY OFFER</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>4</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;DESCRIPTION OF COMMON STOCK</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>4</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;DESCRIPTION OF WARRANTS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>4</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;PLAN OF DISTRIBUTION</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>6</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;VALIDITY OF SECURITIES</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>8</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;EXPERTS</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>8</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>8</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;&nbsp;&nbsp;INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman" SIZE=2>9</FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>You should rely only on the
information contained in or incorporated by reference into this prospectus supplement and
the accompanying prospectus.  We have not authorized anyone to provide you with different
information.  If anyone provides you with different or inconsistent information, you
should not rely on it.  We are not making an offer to sell these securities in any
jurisdiction where the offer or sale is not permitted.  The information in this
prospectus supplement and the accompanying prospectus is accurate only as of the date it
is presented.  Our business, financial condition, results of operations and prospects may
have changed since these dates. </FONT></P>


<p align=center>
<font size=2>S - 2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ABOUT THIS PROSPECTUS SUPPLEMENT </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This prospectus supplement and the
accompanying prospectus dated July 1, 2008 (as supplemented and amended to date) are part
of a &#147;shelf&#148; registration statement on Form S-3 filed with the Securities and Exchange
Commission, and declared effective by the Securities and Exchange Commission on July 1,
2008. By using a &#147;shelf&#148; registration statement, we may sell shares of common stock and
warrants to purchase common stock as described in the accompanying prospectus from time
to time in one or more offerings up to a total of $15,000,000.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>These documents contain important
information you should consider when making your investment decision.  The accompanying
prospectus provides you with a general description of the securities we may offer.  This
prospectus supplement contains information about the securities offered by this
prospectus supplement.  This prospectus supplement may add, update or change information
in the accompanying prospectus.  You should rely only on the information contained in
this prospectus supplement, the accompanying prospectus or incorporated by reference into
this prospectus supplement and the accompanying prospectus.  We have not authorized
anyone to provide you with any other information. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This prospectus supplement does not
constitute an offer to sell, or a solicitation of an offer to buy, the securities offered
hereby in any jurisdiction where, or to any person to whom, it is unlawful to make such
offer or solicitation. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information contained in this
prospectus supplement is accurate only as of the date of this prospectus supplement and
the accompanying prospectus, regardless of the time of delivery of this prospectus or of
any sale of securities. </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>THE OFFERING </FONT></P>



<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH></TH>
     <TH> </TH>
     <TH></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="40%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Common stock and warrants offered by us pursuant to this prospectus</FONT></TD>
     <TD WIDTH="3%"> </TD>
     <TD WIDTH="57%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">  888,406 shares of common stock, plus warrants to purchase up to
                                      additional 488,623 shares of common stock. This prospectus also
                                                     covers the shares of common stock issuable upon exercise of the
                                                     warrants offered hereby.</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Common stock outstanding as of March 31, 2009</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">13,676,836 shares of common stock.</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Warrants outstanding as of March 31, 2009</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Warrants to purchase up to 9,400,216 shares of common stock at a
                                                     weighted average purchase price of $2.48 per share. (1)</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Common stock to be outstanding after this offering (pro forma as of March 31, 2009, excluding
outstanding warrants to purchase 9,400,216 shares
with a weighted average exercise price of $2.48 per
share)</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">14,565,242 shares of common stock, or 15,053,865 shares of common
           stock if the warrants sold in this offering are fully exercised.
    (1)</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Common stock to be outstanding after this offering
(pro forma as of March 31, 2009 including
outstanding warrants to purchase 9,400,216 shares
with a weighted average exercise price of $2.48 per
share)</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">23,965,458 shares of common stock, or 24,454,081 shares of common
            stock, if the warrants sold in this offering are fully exercised.
    (1)</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Terms of warrants offered by us pursuant to this prospectus   </FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Five year term commencing 6 months after issuance, $1.96 per share
                                        exercise price</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Use of proceeds</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">We intend to use the net proceeds from this offering to fund the
                                                     initiation of our Phase-I clinical trials in the USA and Germany,
                                                     as well as related pre-clinical research and other research and
                                                     development expenses and for general working capital and
                                                     administrative expenses. See "Use of Proceeds" on page S-4.</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Nasdaq Capital Market common stock symbol </FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">PSTI</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Risk factors</FONT></TD>
     <TD> </TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">This investment involves a high degree of risk. See "Risk Factors"
                                                     on page S-4 of this prospectus supplement and in our last Annual
                                                     Report on Form 10-K filed with the SEC.</FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1)  Excludes options outstanding
on March 31, 2009, to purchase a total of 2,522,356 shares of common stock at a
weighted-average exercise price of $4.01 per share. </FONT></P>

<p align=center>
<font size=2>S - 3</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>



<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>RISK FACTORS </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment
in our common stock and/or warrants involves a high degree of risk. Before making an
investment decision, you should carefully consider the risks and uncertainties described
below, together with all of the other information appearing in the accompanying
prospectus or incorporated by reference therein, in light of your particular investment
objectives and financial circumstances before you invest in our securities. In
particular, we urge you to read the material under &#147;Risk Factors&#148; beginning on
page 12 of our Annual Report on Form 10-K for our 2008 fiscal year, as filed with the
Securities and Exchange Commission. If any of these risks actually occurs, our business,
financial condition, results of operations and future growth prospects would be
materially adversely affected. The trading price of our securities could decline due to
any of these risks, and you may lose all or part of your investment. This prospectus, any
prospectus supplement and the information incorporated by reference into this prospectus
and any prospectus supplement also contain forward-looking statements that involve risks
and uncertainties. Our actual results could differ materially from those anticipated in
these forward-looking statements as a result of certain factors, including the risks so
mentioned. Please note the following additional risk factor.  </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conflict
with Prior Financing Agreement</U> </FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our subscription agreement for our May 2007 equity financing (the &#147;Prior Financing
Agreement&#148;), there is a provision that requires us for a period of four years
(subject to acceleration under certain circumstances) not to sell any of our common stock
for less than $.0125 per share. The Prior Financing Agreement provides that any sale
below that number must be preceded by a consent from each purchaser in the placement.
Since that date, we have effected a one-for-200 reverse stock split.  </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have decided to proceed with this offering notwithstanding this provision for the
following reasons:  </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT size="2" face="Wingdings 2">&#151;</font></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The
agreement does not contain any provisions for the adjustment of the specified minimum
price in the event of stock splits and the like. If such agreement were to have contained
such a provision, the floor price would be $2.50, which is more than the offering price
of this offering. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT size="2" face="Wingdings 2">&#151;</font></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The
majority of purchasers in the private placement have sold the stock purchased in the
placement, and thus the number of purchasers whose consent is purportedly required has
been substantially reduced. The number of shares outstanding as to which this provision
currently applies according the information supplied by our transfer agent is
approximately 1.8 million shares of common stock. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT size="2" face="Wingdings 2">&#151;</font></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>An
agreement that prevents our Board of Directors from issuing shares that are necessary to
finance our business may be unenforceable. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT size="2" face="Wingdings 2">&#151;</font></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Even
if the agreement were considered enforceable and the share price number were to be
adjusted for our reverse stock split, we believe that there would be no damage from this
offering to the holders of our shares whose consent is purportedly required. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that a court were to hold that the issuance of shares below $2.50 per share
would violate the Prior Financing Agreement, it is unclear what remedy the court might
impose. If the court were to impose a remedy that would be the equivalent of an
anti-dilution provision (which is not contained in the Prior Financing Agreement), any
issuance of shares would be dilutive to our shareholders, including those who purchase
shares in the current offering.  </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>USE OF PROCEEDS </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The proceeds we will receive from the
offering of units will be $1,332,610, before deducting the placement agency fee and
estimated offering expenses payable by us and excluding any proceeds from the potential
exercise of warrants offered hereby. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We intend to use the net proceeds
from this offering to fund the initiation of our Phase-I clinical trials in the USA and
Germany, as well as related pre-clinical research and other research and development
expenses and for general working capital and administrative expenses. The amounts and
timing of the expenditures may vary significantly depending on numerous factors, such as
the progress of our clinical trials and other research and development efforts,
technological advances and the competitive environment for our products. Although we have
no specific agreements, commitments or understandings with respect to any acquisition, we
evaluate acquisition opportunities and engage in related discussions with other companies
from time to time. Pending the use of the net proceeds, we intend to invest the net
proceeds in short-term, interest-bearing, investment-grade securities. </FONT></P>

<p align=center>
<font size=2>S - 4</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our management will have broad
discretion in the application of the net proceeds and investors will be relying upon the
judgment of our management regarding the application of these proceeds. We reserve the
right to change the use of these proceeds. Depending upon the timing of receipt of any
warrant exercise shares proceeds, we would use such proceeds for such corporate purposes
as our management and Board of Directors may approve at the time. Such purposes may be
different from today&#146;s purposes. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>DILUTION </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>If you purchase our common stock in
this offering (either as a component of units or upon warrant exercise), your interest
will be diluted to the extent of the difference between the public offering price per
share and the net tangible book value per share of our common stock after this offering.
We calculate net tangible book value per share by dividing the net tangible book value,
tangible assets less total liabilities, by the number of outstanding shares of our common
stock. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our net tangible book value at March
31, 2009, was $3.1 million, or $0.23 per share, based on 13,676,836 shares of our common
stock outstanding as of that date. After giving effect to the sale of 888,406 shares of
common stock by us at a public offering price of $1.50 per share, less the placement
agency fees, our net tangible book value as of March 31, 2009 would have been
approximately $4.3 million, or $0.30 per share. This represents an immediate increase in
the net tangible book value of approximately $0.07 per share to existing stockholders and
an immediate dilution of $1.20 per share to investors in this offering. The following
table illustrates this per share dilution: </FONT></P>




<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600" ALIGN="Center">
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#cceeff">
     <TD WIDTH="66%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>Public offering price per share</FONT></TD>
     <TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD WIDTH="11%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD WIDTH="11%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2> 1.50</FONT></TD>
        <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>Net tangible book value per share as of March 31, 2009</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>    0.23</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#cceeff">
     <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>Increase in net tangible book value per share after this offering</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>    0.07</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>Net tangible book value per share after this offering</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2> 0.30</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#cceeff">
     <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>Dilution per share to new investors</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2> 1.20</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR>
     <TD COLSPAN=3></TD>
     <TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD>
     <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#808080 SIZE=1></TD><TD></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The foregoing per share dilution does
not give effect to the potential exercise of the warrants offered hereby. Assuming the
sale of all units offered hereby and also the exercise of all warrants within such units,
the per share dilution would be as follows: </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our net tangible book value at March
31, 2009, was $3.1 million or $0.23 per share, based on 13,676,836 shares of our common
stock outstanding as of that date.&nbsp; After giving effect to the sale of
&nbsp;1,377,029 shares of common stock (inclusive of 488,623 warrant shares) by us at a
blended public offering price of $1.66 per share, less the placement agency fees, our net
tangible book value as of March 31, 2009, would have been approximately $5.3 million, or
$0.35 per share.&nbsp; This represents an immediate increase in the net tangible book
value of approximately $0.12 per share to existing stockholders and an immediate dilution
of $1.31&nbsp;per share to investors in this offering. The following table illustrates
this per share dilution: </FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600" ALIGN="Center">
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH COLSPAN=3><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#cceeff">
     <TD WIDTH="66%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>Public offering price per share</FONT></TD>
     <TD WIDTH="1%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD WIDTH="11%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD WIDTH="1%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD WIDTH="11%" ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2> 1.66</FONT></TD>
        <TD WIDTH="3%" ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>Net tangible book value per share as of March 31, 2009</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>    0.23</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#cceeff">
     <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>Increase in net tangible book value per share after this offering</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>    0.12</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>Net tangible book value per share after this offering</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2> 0.35</FONT></TD>
        <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR VALIGN="BOTTOM" BGCOLOR="#cceeff">
     <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>Dilution per share to new investors</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD>
     <TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2>$</FONT></TD><TD ALIGN="RIGHT"><FONT FACE="Times New Roman" SIZE=2> 1.31</FONT></TD>
        <TD ALIGN="LEFT"><FONT FACE="Times New Roman" SIZE=2>&nbsp;</FONT></TD></TR>
<TR>
     <TD COLSPAN=3></TD>
     <TD COLSPAN=2 ALIGN=RIGHT></TD><TD></TD>
     <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#808080 SIZE=1></TD><TD></TD></TR>
</TABLE>
<BR>

<p align=center>
<font size=2>S - 5</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PLAN OF DISTRIBUTION </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We have entered into a placement
agency agreement, dated as of March 2, 2009, with Rodman &amp; Renshaw, LLC. Subject to
the terms and conditions contained in the placement agency agreement, Rodman &amp; Renshaw,
LLC has agreed to act as the placement agent in connection with the sale of shares of
common stock and warrants to purchase shares of common stock. The placement agent is not
purchasing or selling any securities by this prospectus supplement and the accompanying
prospectus, nor is it required to arrange the purchase or sale of any specific number or
dollar amount of the securities, but it has agreed to use its best efforts to arrange for
the sale of all of the securities in this offering. There is no required minimum number of
securities that must be sold as a condition to completion of the offering. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The placement agency agreement
provides that the obligations of the placement agent and the purchasers are subject to
certain conditions precedent, including, among other things, the receipt of certain
customary opinions, letters and closing certificates. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We have entered into purchase
agreements directly with purchasers in connection with this offering, and we will only
sell to purchasers who have entered into purchase agreements. We currently anticipate that
the closing of the sale of the units offered hereby will take place on or before May 8,
2009. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Upon closing, we will deliver to each
purchaser delivering funds the number of shares purchased by such purchaser through the
facilities of The Depository Trust Company and will deliver a physical warrant certificate
to each Purchaser within three business days. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We have agreed to pay the placement
agent an aggregate fee equal to 6.0% of the gross proceeds from the sale of units in this
offering. We are not obligated to pay the placement agent any additional fee when and if
the warrants are exercised. In addition, we have agreed to pay the fees, disbursements and
other charges of counsel to the placement agent in an amount equal to 0.8% of gross
proceeds, but not to exceed $15,000. In addition, we agreed to grant compensation warrants
to the placement agent to purchase a number of our common stock shares equal to 6.0% of
the actual purchase price of $1,332,610 ($79,957) divided by $1.50. The compensation
warrants will be substantially on the same terms as the warrants offered hereby, except
that the compensation warrants will have an exercise price equal to $1.875 per share, will
expire five years from the date of this Prospectus Supplement, and will otherwise comply
with Financial Institutions Regulatory Authority, or FINRA, Rule 5110(g)(1) in that for a
period of six months after the issuance date of the compensation warrants (which shall not
be earlier than the closing date of the offering pursuant to which the compensation
warrants are being issued), neither the compensation warrants nor any warrant shares
issued upon exercise of the compensation warrants shall be sold, transferred, assigned,
pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put,
or call transaction that would result in the effective economic disposition of the
securities by any person for a period of 180 days immediately following the date of
effectiveness or commencement of sales of the offering pursuant to which the compensation
warrants are being issued, except the transfer of any security: </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>i. </FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>by
operation of law or by reason of reorganization of the Company; </FONT></TD>
<TD WIDTH=30%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ii. </FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>to
any FINRA member firm participating in this offering and the officers or
               partners thereof, if all securities so transferred remain subject to the
lock-up                restriction described above for the remainder of the time period; </FONT></TD>
<TD WIDTH=30%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>iii. </FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>if
the aggregate amount of securities of the Company held by Rodman &amp;               Renshaw,
LLC or related person do not exceed 1% of the securities being offered; </FONT></TD>
<TD WIDTH=30%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>iv. </FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>that
is beneficially owned on a pro-rata basis by all equity owners of an
               investment fund, provided that no participating member manages or
otherwise                directs investments by the fund, and participating members in
the aggregate do                not own more than 10% of the equity in the fund; or </FONT></TD>
<TD WIDTH=30%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>v. </FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
exercise or conversion of any security, if all securities received remain
               subject to the lock-up restriction set forth above for the remainder of
the time                period. </FONT></TD>
<TD WIDTH=30%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<BR>

<p align=center>
<font size=2>S - 6</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to a requirement by FINRA,
the maximum commission or discount to be received by any FINRA member or independent
broker/dealer may not be greater than 8.0% of the gross proceeds received by us for the
sale of any securities being registered pursuant to SEC Rule 415. Assuming that all of the
securities offered hereby are sold, the placement agent&#146;s fee will be approximately
$80,000. Because there is no minimum offering amount required as a condition to closing in
this offering, however, the actual total offering fees, if any, are not presently
determinable and may be substantially less than such amount. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We have agreed to indemnify the
placement agent against certain liabilities, including civil liabilities under the
Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended,
and to contribute to payments that the placement agent may be required to make in respect
of those liabilities. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The placement agent has informed us
that it will not engage in over-allotment, stabilizing transactions or syndicate covering
transactions in connection with this offering. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The transfer agent for our common
stock is American Stock Transfer &amp; Trust Company, Brooklyn, New York. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our common stock is traded on the Nasdaq
Capital Market and the Frankfurt Stock Exchange under the symbols &#147;PSTI&#148; and
&#147;PJT&#148;, respectively. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The placement agent may distribute
this prospectus supplement and the accompanying prospectus electronically. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The placement agency agreement has been
included as an exhibit to a Current Report on Form 8-K that was filed with the SEC on May
6, 2009 and has been incorporated by reference into the registration statements of which
this prospectus supplement forms a part. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>From time to time in the ordinary
course of its business, the placement agent or its affiliates may in the future engage in
investment banking, commercial banking and/or other services with us and our affiliates
for which it may in the future receive customary fees and expenses. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>DESCRIPTION OF WARRANTS </FONT></H1>


<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
warrants to be issued in this offering represent the right to purchase up to 488,623
shares of common stock at an initial exercise price of $1.96 per share. Each warrant may
be exercised at any time and from time to time on or after November 5, 2009 and through
and including November 4, 2014. </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exercise&nbsp; </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of the warrants may exercise their warrants to purchase shares of our common stock on or
before the expiration date by delivering (i)&nbsp;an exercise notice, appropriately
completed and duly signed, and (ii)&nbsp;if such holder is not utilizing the cashless
exercise provisions, payment of the exercise price for the number of shares with respect
to which the warrant is being exercised. Warrants may be exercised in whole or in part,
but only for full shares of common stock, and any portion of a warrant not exercised prior
to the expiration date shall be automatically exercised by way of cashless exercise (to
the extent applicable) on the expiration date. We provide certain rescission, compensation
and buy-in rights to a holder if we fail to deliver the shares of common stock underlying
the warrants by the third trading day after delivery to us of the exercise notice. With
respect to the rescission rights, the holder has the right to rescind the exercise. The
buy-in rights apply if after such third trading day the holder purchases (in an open
market transaction or otherwise) shares of our common stock to deliver in satisfaction of
a sale by the holder of the warrant shares that the holder anticipated receiving from us
upon exercise of the warrant. In this event, we will: </FONT></P>

<p align=center>
<font size=2>S - 7</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 0-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT size="2" face="Wingdings 2">&#151;</font></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>pay
cash to the holder in an amount equal to the excess (if any) of the buy-in price over the
product of (A)&nbsp;such number of shares of common stock, times (B)&nbsp;the price at
which the sell order giving rise to holder&#146;s purchase obligation was executed;&nbsp;and </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 0-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT size="2" face="Wingdings 2">&#151;</font></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>at
the election of holder, either (A)&nbsp;reinstate the portion of the warrant as to such
number of shares of common stock, or (B)&nbsp;deliver to holder a certificate or
certificates representing such number of shares of common stock. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the warrant holders are entitled to a &#147;cashless exercise&#148; option if,
at any time of exercise, there is no effective registration statement registering, or no
current prospectus available for, the issuance or resale of the shares of common stock
underlying the warrants. This option entitles the warrant holder to elect to receive
fewer shares of common stock without paying the cash exercise price. The number of shares
to be issued would be determined by a formula based on the total number of shares with
respect to which the warrant is being exercised, the volume weighted average of the
prices per share of our common stock on the trading date immediately prior to the date of
exercise and the applicable exercise price of the warrants.  </FONT></P>



<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares of common stock issuable on exercise of the warrants will be, when issued in
accordance with the warrants, duly and validly authorized, issued and fully paid and
non-assessable. We will authorize and reserve at least that number of shares of common
stock equal to the number of shares of common stock issuable upon exercise of all
outstanding warrants. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Delivery of
Certificates&nbsp; </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the holder&#146;s exercise of a warrant, we will promptly, but in no event later than
three trading days after the exercise date, issue and deliver, or cause to be issued and
delivered, a certificate for the shares of common stock issuable upon exercise of the
warrant. In addition, we will, if the holder provides the necessary information to us,
issue and deliver the shares electronically through The Depository Trust&nbsp;Corporation
through its Deposit Withdrawal Agent Commission System or another established clearing
corporation performing similar functions. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Certain Adjustments&nbsp; </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
exercise price and the number of shares of common stock purchasable upon the exercise of
the warrants are subject to adjustment upon the occurrence of the following events: </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U> </FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any time while the warrant is outstanding, we (i) pay a stock dividend or otherwise
make a distribution on any class of capital stock that is payable in shares of common
stock, (ii) subdivide outstanding shares of common stock into a larger number of shares,
(iii) combine outstanding shares of common stock into a smaller number of shares, or (iv)
issue by reclassification of common stock any shares of capital stock, then in each such
case the exercise price shall be multiplied by a fraction of which the numerator shall be
the number of shares of common stock outstanding immediately before such event and of
which the denominator shall be the number of shares of common stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this
Warrant shall be proportionately adjusted such that the aggregate exercise price of the
warrant shall remain unchanged.  </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U></FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any time while the warrant is outstanding, we issue rights, options or warrants to all
holders of our common stock entitling them to purchase our common stock at a price per
share less than the volume weighted average price on the date of the issuance of such
rights, options or warrants, then the exercise price shall be multiplied by a fraction,
of which the denominator shall be the number of shares of common stock outstanding on the
date of issuance of such rights or warrants plus the number of additional shares of
common stock offered for subscription or purchase, and of which the numerator shall be
the number of shares of common stock outstanding on the date of issuance of such rights
or warrants plus the number of shares which the aggregate offering price of the total
number of shares so offered would purchase at such volume weighted average price.  </FONT></P>


<p align=center>
<font size=2>S - 8</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U></FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any time while the warrant is outstanding, we distribute evidences of our indebtedness
or assets or rights or warrants to purchase any security other than our common stock to
all holders of our common stock, then the exercise price will adjust pursuant to a volume
weighted average price based ratio. </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U></FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any time while the warrant is outstanding, we (i)&nbsp;consolidate or merge with or
into another corporation, (ii)&nbsp;sell all or substantially all of our assets or
(iii)&nbsp;are subject to or complete a tender or exchange offer pursuant to which holders
of our common stock are permitted to tender or exchange their shares for other securities,
cash or property, (iv)&nbsp;effect any reclassification of our common stock or any
compulsory share exchange pursuant to which our common stock is converted into or
exchanged for other securities, cash or property, each, a Fundamental Transaction, then
the holders shall have the right thereafter to receive, upon exercise of the warrant, the
same amount and kind of securities, cash or property as it would have been entitled to
receive upon the occurrence of such Fundamental Transaction if it had been, immediately
prior to such Fundamental Transaction, the holder of the number of warrant shares then
issuable upon exercise of the warrant, or Alternate Consideration. Any successor to us,
surviving entity or the corporation purchasing or otherwise acquiring such assets shall
assume the obligation to deliver to the holder such Alternate Consideration as the Holder
may be entitled to purchase, and the other obligations under the warrant. </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of certain Fundamental Transactions, the holders of the warrants will be
entitled to receive, in lieu of our common stock and at the holders&#146; option, cash in
an amount equal to the value of the remaining unexercised portion of the warrant on the
date of the transaction determined using a Black-Scholes option pricing model with an
expected volatility equal to the 100&nbsp;day historical price volatility obtained from
Bloomberg L.P. as of the trading day immediately prior to the public announcement of the
transaction. </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Notice of Corporate
Action&nbsp; </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will provide notice to holders of the warrants to provide such holders with a practical
opportunity to exercise their warrants and hold common stock in order to participate in or
vote on the following corporate events if we (i) declare a dividend on the common stock,
(ii) declare a special nonrecurring cash dividend on or a redemption of the common stock,
(iii) authorize the granting to all holders of the common stock rights or warrants to
subscribe for or purchase any shares of capital stock of any class or of any rights, (iv)
require the approval of any stockholders in connection with any reclassification of the
common stock, any consolidation or merger to which we are a party, any sale or transfer of
all or substantially all of our assets, any compulsory share exchange whereby the common
stock is converted into other securities, cash or property, or (v) authorize the voluntary
or involuntary dissolution, liquidation or winding up of the affairs of the Company. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Limitations on Exercise&nbsp; </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of warrant shares that may be acquired by the holder upon any exercise of the
warrant shall be limited to the extent necessary to insure that, following such exercise
(or other issuance), the total number of shares of common stock then beneficially owned by
such holder and its affiliates and any other persons whose beneficial ownership of common
stock would be aggregated with the holder&#146;s for purposes of Section&nbsp;13(d) of the
Exchange Act, does not exceed 4.99% of the total number of issued and outstanding shares
of common stock (including for such purpose the shares of common stock issuable upon such
exercise), or Beneficial Ownership Limitation. The holder may elect to change the
Beneficial Ownership Limitation from 4.99% to 9.9% of the total number of issued and
outstanding shares of common stock (including for such purpose the shares of common stock
issuable upon such exercise) upon 61&nbsp;days&#146; prior written notice. </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Additional
Provisions&nbsp; </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
above summary of certain terms and provisions of the warrants is qualified in its entirety
by reference to the detailed provisions of the warrants, the form of which will be filed
as an exhibit to a current report on Form&nbsp;8-K that will be incorporated herein by
reference. We are not required to issue fractional shares upon the exercise of the
warrants. No holders of the warrants will possess any rights as a stockholder under those
warrants until the holder exercises those warrants. The warrants may be transferred
independent of the common stock they were issued with, on a form of assignment, subject to
all applicable laws. </FONT></P>

<p align=center>
<font size=2>S - 9</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>LEGAL MATTERS </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The validity of the securities
offered by this prospectus supplement has been passed upon for us by Zysman, Aharoni,
Gayer &amp; Co./Sullivan &amp; Worcester LLP, Boston, Massachusetts. The placement agent
is being represented in connection with this offering by Feldman Weinstein &amp; Smith,
New York, New York. </FONT></P>

<p align=center>
<font size=2>S - 10</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> </FONT><IMG SRC="pluristem.jpg"></P>






<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$15,000,000 </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>PLURISTEM THERAPEUTICS
INC. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common Stock <BR>Warrants </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We may from time to time sell common
stock and warrants to purchase common stock in one or more offerings for an aggregate
initial offering price of $15,000,000. We refer to the common stock and the warrants to
purchase common stock collectively as the securities. This prospectus describes the
general manner in which our securities may be offered using this prospectus. We will
specify in an accompanying prospectus supplement the terms of the securities to be
offered and sold. We may sell these securities to or through underwriters or dealers,
directly to purchasers or through agents. We will set forth the names of any
underwriters, dealers or agents in an accompanying prospectus supplement.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our common stock is traded on the
NASDAQ Capital Market under the symbol &#147;PSTI&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Investing in our securities involves
risks. See &#147;Risk Factors&#148; on page&nbsp;3 of this prospectus.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus. Any representation
to the contrary is a criminal offense.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This prospectus is dated July 1,
2008.  </FONT></P>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>TABLE OF CONTENTS </FONT></P>


<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TD WIDTH=90% ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>ABOUT THIS PROSPECTUS</FONT></TD>
     <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>2&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>OUR COMPANY</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>3&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>RISK FACTORS</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>3&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>3&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>USE OF PROCEEDS</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>4&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>THE SECURITIES WE MAY OFFER</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>4&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>4&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>DESCRIPTION OF WARRANTS</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>4&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>PLAN OF DISTRIBUTION</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>6&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>VALIDITY OF SECURITIES</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>8&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>EXPERTS</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>8&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>8&nbsp;</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=LEFT><FONT FACE="Times New Roman" SIZE=2>INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></TD>
     <TD ALIGN=RIGHT><FONT FACE="Times New Roman" SIZE=2>9&nbsp;</FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>You should rely only on the
information contained in this prospectus and the documents incorporated by reference in
this prospectus or to which we have referred you. We have not authorized anyone to
provide you with different information. If anyone provides you with different or
inconsistent information, you should not rely on it. This prospectus does not constitute
an offer to sell, or a solicitation of an offer to purchase, the securities offered by
this prospectus in any jurisdiction to or from any person to whom or from whom it is
unlawful to make such offer or solicitation of an offer in such jurisdiction. You should
not assume that the information contained in this prospectus or any document incorporated
by reference is accurate as of any date other than the date on the front cover of the
applicable document. Neither the delivery of this prospectus nor any distribution of
securities pursuant to this prospectus shall, under any circumstances, create any
implication that there has been no change in the information set forth or incorporated by
reference into this prospectus or in our affairs since the date of this prospectus. Our
business, financial condition, results of operations and prospects may have changed since
that date.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ABOUT THIS PROSPECTUS  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This prospectus is part of a
registration statement that we filed with the Securities and Exchange Commission using a
&#147;shelf&#148; registration process. Under this shelf registration process, we may,
from time to time, sell any combination of the securities described in this prospectus in
one or more offerings up to a total dollar amount of $15,000,000. This prospectus
describes the securities we may offer and the general manner in which our securities may
be offered by this prospectus. Each time we sell securities, we will provide a prospectus
supplement that will contain specific information about the terms of that offering. We
may also add, update or change in the prospectus supplement any of the information
contained in this prospectus. To the extent there is a conflict between the information
contained in this prospectus and the prospectus supplement, you should rely on the
information in the prospectus supplement, provided that if any statement in one of these
documents is inconsistent with a statement in another document having a later date&nbsp;&#150; for
example, a document incorporated by reference in this prospectus or any prospectus
supplement&nbsp;&#150; the statement in the document having the later date modifies or
supersedes the earlier statement.  </FONT></P>

<p align=center>
<font size=2>2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>OUR COMPANY </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We are engaged in the business of
the development of mesenchymal and stem cell production technology and the
commercialization of cell therapy products.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>From May 2003 until March 2006, our
business was focused on the development of stem cell production technology. Originally,
our plan was to develop that technology to the point where we could license it to medical
scientists and practitioners for their use in producing cell therapy products for sale in
the marketplace. On March 6, 2006, we announced that our company was taking a new
direction. Instead of looking to license our stem cell production technology, we decided
to focus on developing the technology with the goal of producing cell therapy products
ourselves for sale in the marketplace. On July 5, 2006 and October 16, 2006, we announced
that our subsidiary, Pluristem Ltd., achieved a breakthrough in our preclinical study of
bone marrow transplantation: The preclinical study showed that by adding PLX-I (PLacenta
eXpanded cells) to Umbilical cord blood (UCB) stem cells during bone marrow
transplantation (BMT), hematopoietic stem cell engraftment in mice showed up to a 500%
increase in engraftment after irradiation and chemotherapy. On January 8, 2008, we
announced that we achieved favorable results in demonstrating a revascularization effect
after using our propriety PLX-PAD cells for the treatment of limb ischemia associated
with peripheral artery disease (PAD). On April 7, 2008, we announced that the results
from Fraunhofer Institute&#146;s additional pre-clinical study utilizing our proprietary
PLacental eXpanded (PLX) cells in treating ischemic stroke showed statistical
significance utilizing functional as well as anatomical endpoints.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On November 23, 2007, we changed our
name to Pluristem Therapeutics Inc. On November 26, 2007, we effected a one for two
hundred reverse stock split. Accordingly, all references to number of shares, common
stock and per share data have been adjusted to reflect the stock split on a retroactive
basis.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On December 10, 2007, our shares of
common stock began trading on the NASDAQ Capital Market under the symbol &#147;PSTI.&#148; The
shares were previously traded on the OTC Bulletin Board under the trading symbol &#147;PLRS.OB&#148;.
On May 7, 2007, our shares also began trading on Europe&#146;s Frankfurt Stock Exchange,
under the symbol &#147;PJT.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Effective on June 4, 2008, our
authorized number of shares of our common stock was increased from 7,000,000 shares to
30,000,000 shares.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our executive offices are located at
MATAM Advanced Technology Park, Building No. 20, Haifa, Israel, our telephone number is
011 972 74 710 7171 and our website address is <U>www.pluristem.com</U> . The information
on our website is not incorporated by reference in this prospectus and should not be
considered to be part of this prospectus. Our website address is included in this
prospectus as an inactive technical reference only. Our name and logo and the names of
our products are our trademarks or registered trademarks. Unless the context otherwise
requires, references in this prospectus to &#147;Pluristem,&#148;&#147;we,&#148; &#147;us,&#148; and
&#147;our&#148; refer to Pluristem Therapeutics Inc. and it subsidiaries as required by
the context.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>RISK FACTORS </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>An investment in our securities
involves significant risks. You should carefully consider the risk factors contained in
any prospectus supplement and in our filings with the Securities and Exchange Commission,
as well as all of the information contained in this prospectus, any prospectus supplement
and the documents incorporated by reference in this prospectus, before you decide to
invest in our securities. The risks and uncertainties we have described are not the only
ones we face. Additional risks and uncertainties not presently known to us or that we
currently deem immaterial may also affect our operations.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SPECIAL
NOTE&nbsp;REGARDING FORWARD-LOOKING INFORMATION </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This prospectus, any prospectus
supplement and the documents we incorporate by reference in this prospectus contain
forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and other Federal securities laws. All statements, other than statements of
historical fact, that we include in this prospectus, any prospectus supplement and in the
documents we incorporate by reference in this prospectus, may be deemed forward-looking
statements for purposes of the Securities Act of 1933, or the Securities Act, and the
Securities Exchange Act of 1934, or the Exchange Act. We use the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;will,&#148; &#147;would&#148; and
similar expressions to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. We cannot guarantee that we
actually will achieve the plans, intentions or expectations disclosed in our
forward-looking statements and, accordingly, you should not place undue reliance on our
forward-looking statements. There are a number of important factors that could cause
actual results or events to differ materially from the forward-looking statements that we
make, including the factors included in the documents we incorporate by reference in this
prospectus. You should read these factors and the other cautionary statements made in the
documents we incorporate by reference as being applicable to all related forward-looking
statements wherever they appear in this prospectus, any prospectus supplement and any
document incorporated by reference. We caution you that, except as otherwise required by
law, we do not undertake any obligation to update forward-looking statements we make.  </FONT></P>

<p align=center>
<font size=2>3</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>USE OF PROCEEDS </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Unless we otherwise indicate in the
applicable prospectus supplement, we currently intend to use the net proceeds from the
sale of the securities for research and product development activities, and for working
capital and other general corporate purposes.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We may set forth additional
information on the use of net proceeds from the sale of securities we offer under this
prospectus in a prospectus supplement relating to the specific offering. Pending the
application of the net proceeds, we intend to invest the net proceeds in
investment-grade, interest-bearing securities.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>THE SECURITIES WE MAY
OFFER </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The descriptions of the securities
contained in this prospectus, together with the applicable prospectus supplement,
summarize the material terms and provisions of the various types of securities that we
may offer. We will describe in the applicable prospectus supplement relating to any
securities the particular terms of the securities offered by that prospectus supplement.
If we so indicate in the applicable prospectus supplement, the terms of the securities
may differ from the terms we have summarized below. We may also include in the prospectus
supplement information, where applicable, about material United States federal income tax
consequences relating to the securities, and the securities exchange or market, if any,
on which the securities will be listed.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We may sell from time to time, in
one or more offerings, one or more of the following securities:  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>common
stock; and</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>warrants
to purchase common stock.</FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The total initial offering price of
all securities that we may issue in these offerings will not exceed $15,000,000.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>DESCRIPTION OF COMMON
STOCK </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>For a description of the material
terms and provisions of our common stock and any other class of our securities which
qualifies or limits our common stock, please see the applicable prospectus supplement, as
well as the description of our capital stock in our Registration Statement on Form&nbsp;8-A,
as amended, which is incorporated by reference in this prospectus.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>DESCRIPTION OF WARRANTS </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The following description, together
with the additional information we may include in any applicable prospectus supplement,
summarizes the material terms and provisions of the warrants that we may offer under this
prospectus and the related warrant agreements and warrant certificates. While the terms
summarized below will apply generally to any warrants that we may offer, we will describe
the particular terms of any series of warrants in more detail in the applicable
prospectus supplement. If we so indicate in a prospectus supplement, the terms of any
warrants offered under that prospectus supplement may differ from the terms we describe
below. Specific warrant agreements will contain additional important terms and provisions
and will be incorporated by reference as an exhibit to the registration statement.  </FONT></P>

<p align=center>
<font size=2>4</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>General</U> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We may issue warrants for the
purchase of common stock in one or more series. We may issue warrants independently or
together with common stock, and the warrants may be attached to or separate from the
common stock.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We will evidence each series of
warrants by warrant certificates that we will issue under a separate agreement or by
warrant agreements that we will enter into directly with the purchasers of the warrants.
If we evidence warrants by warrant certificates, we will enter into a warrant agreement
with a warrant agent. We will indicate the name and address of the warrant agent, if any,
in the applicable prospectus supplement relating to a particular series of warrants.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We will describe in the applicable
prospectus supplement the terms of the series of warrants, including:  </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
offering price and aggregate number of warrants offered;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
currency for which the warrants may be purchased or exercised;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>if
applicable, the terms of the common stock with which the warrants are issued and the
number of               warrants issued with such common stock;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>if
applicable, the date on and after which the warrants and the related common stock will be
separately               transferable;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
number of shares of common stock purchasable upon the exercise of one warrant and the
price at which these shares may be purchased upon such exercise; </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
manner in which the warrants may be exercised, which may include by cashless exercise;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
effect of any merger, consolidation, sale or other disposition of our business on the
warrant               agreement and the warrants;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
terms of any rights to redeem or call the warrants;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>any
provisions for changes to or adjustments in the exercise price or number of shares of
common stock               issuable upon exercise of the warrants;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
dates on which the right to exercise the warrants will commence and expire;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
manner in which the warrant agreement and warrants may be modified;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
material United States federal income tax consequences of holding or exercising the
warrants;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
terms of the common stock issuable upon exercise of the warrants; and</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>any
other specific terms, preferences, rights or limitations of or restrictions on the
warrants.</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Before exercising their warrants,
holders of warrants will not have any of the rights of holders of the common stock
purchasable upon such exercise, including the right to receive dividends, if any, or
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if
any.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P> <FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Exercise of Warrants</U> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Each warrant will entitle the holder
to purchase the number of shares of common stock that we specify in the applicable
prospectus supplement at the exercise price that we describe in the applicable prospectus
supplement. Unless we otherwise specify in the applicable prospectus supplement, holders
of the warrants may exercise the warrants at any time up to 5:00&nbsp;P.M., Eastern U.S.
time, on the expiration date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised warrants will become
void.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Holders of the warrants may exercise
the warrants by delivering to the warrant agent or us the warrant certificate or warrant
agreement representing the warrants to be exercised together with specified information,
and by paying the required amount to the warrant agent or us in immediately available
funds, as provided in the applicable prospectus supplement. We will set forth on the
reverse side of the warrant certificate or in the warrant agreement and in the applicable
prospectus supplement the information that the holder of the warrant will be required to
deliver to the warrant agent or us in connection with such exercise. Certain of the
warrants may entitle the holders thereof to &#147;cashless exercise&#148; under certain
circumstances. This option entitles the warrant holder to elect to receive fewer shares
of common stock without paying the cash exercise price.&nbsp;&nbsp;The number of shares
to be issued would be determined by a formula based on the total number of shares to
which the warrant holder is entitled, the market price of the common stock on the date of
exercise or the days prior to the exercise and the applicable exercise price of the
warrants.  </FONT></P>

<p align=center>
<font size=2>5</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Upon receipt of the required
payment, if need to, and the warrant certificate or the warrant agreement, as applicable,
properly completed and duly executed at the corporate trust office of the warrant agent,
if any, at our offices or at any other office indicated in the applicable prospectus
supplement, we will issue and deliver the common stock purchasable upon such exercise. If
fewer than all of the warrants represented by the warrant certificate or warrant
agreement are exercised, then we will issue a new warrant certificate or warrant
agreement for the remaining amount of warrants.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P> <FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Enforceability of Rights by
Holders of Warrants</U> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>If we appoint a warrant agent, any
warrant agent will act solely as our agent under the applicable warrant agreement and
will not assume any obligation or relationship of agency or trust with any holder of any
warrant. A single bank or trust company may act as warrant agent for more than one issue
of warrants. A warrant agent will have no duty or responsibility in case of any default
by us under the applicable warrant agreement or warrant, including any duty or
responsibility to initiate any proceedings at law or otherwise, or to make any demand
upon us. Any holder of a warrant may, without the consent of the related warrant agent or
the holder of any other warrant, enforce by appropriate legal action its right to
exercise, and receive the securities purchasable upon exercise of, its warrants.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PLAN OF DISTRIBUTION </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We may sell the securities being
offered hereby in one or more of the following ways from time to time:  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>through
agents to the public or to investors;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>to
one or more underwriters for resale to the public or to investors;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>in
&#147;at the market offerings,&#148; within the meaning of Rule 415(a)(4) of the
Securities Act, to or through a market maker or into an existing trading market, on an
exchange or otherwise; </FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>directly
to investors in privately negotiated transactions;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>directly
to a purchaser pursuant to what is known as an "equity line of credit" as described
below; or</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>through
a combination of these methods of sale.</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The securities that we distribute by
any of these methods may be sold, in one or more transactions, at:  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a
fixed price or prices, which may be changed;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>market
prices prevailing at the time of sale;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>prices
related to prevailing market prices; or</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>negotiated
prices.</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The accompanying prospectus
supplement will describe the terms of the offering of our securities, including:  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
name or names of any agents or underwriters;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>any
securities exchange or market on which the common stock may be listed;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>the
purchase price and commission, if any, to be paid in connection with the sale of the
securities being offered and the proceeds we will receive from the sale; </FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>any
over-allotment options pursuant to which underwriters may purchase additional securities
from us;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>any
underwriting discounts or agency fees and other items constituting underwriters' or
agents'               compensation;</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>any
public offering price; and</FONT></TD>
</TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>any
discounts or concessions allowed or reallowed or paid to dealers.</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>If underwriters are used in the
sale, they will acquire the securities for their own account and may resell the
securities from time to time in one or more transactions, including negotiated
transactions, at a fixed public offering price or at varying prices determined at the
time of the sale. The obligations of the underwriters to purchase the securities will be
subject to the conditions set forth in the applicable underwriting agreement. We may
offer the securities to the public through underwriting syndicates represented by
managing underwriters or by underwriters without a syndicate. Subject to certain
conditions, the underwriters will be obligated to purchase all the securities offered by
the prospectus supplement. We may change from time to time the public offering price and
any discounts or concessions allowed or reallowed or paid to dealers.  </FONT></P>



<p align=center>
<font size=2>6</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We may also sell securities pursuant
to an &#147;equity line of credit&#148;. In such event, we will enter into a common stock
purchase agreement with the purchaser to be named therein, which will be described in a
Current Report on Form 8-K that we will file with the SEC. In that Form 8-K, we will
describe the total amount of money that we may require the purchaser to invest under the
purchase agreement and the other terms of purchase, and any rights that the purchaser is
granted to purchase securities from us. In addition to our issuance of shares of common
stock to the equity line purchaser pursuant to the purchase agreement, this prospectus
(and the applicable prospectus supplement or post-effective amendment) also covers the
resale of those shares from time to time by the equity line purchaser to the public. The
equity line purchaser will be considered an &#147;underwriter&#148; within the meaning of
Section 2(a)(11) of the Securities Act. Its resales may be effected through a number of
methods, including without limitation, ordinary brokerage transactions and transactions
in which the broker solicits purchasers and block trades in which the broker or dealer so
engaged will attempt to sell the shares as agent, but may position and resell a portion
of the block as principal to facilitate the transaction. The equity line purchaser will
be bound by various anti-manipulation rules of the SEC and may not, for example, engage
in any stabilization activity in connection with its resales of our securities and may
not bid for or purchase any of our securities or attempt to induce any person to purchase
any of our securities other than as permitted under the Exchange Act.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We may sell our securities directly
or through agents we designate from time to time. We will name any agent involved in the
offering and sale of our common stock, and we will describe any commissions we will pay
the agent in the prospectus supplement. Unless the prospectus supplement states
otherwise, our agent will act on a best-efforts basis for the period of its appointment.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We may provide underwriters and
agents with indemnification against civil liabilities related to this offering, including
liabilities under the Securities Act, or contribution with respect to payments that the
underwriters or agents may make with respect to these liabilities. Underwriters and
agents may engage in transactions with, or perform services for, us in the ordinary
course of business. We will describe such relationships in the prospectus supplement
naming the underwriter or agent and the nature of any such relationship.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Rules of the Securities and Exchange
Commission may limit the ability of any underwriters to bid for or purchase securities
before the distribution of the shares of common stock is completed. However, underwriters
may engage in the following activities in accordance with the rules:  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Stabilizing
transactions</I> &#150;&nbsp;Underwriters may make bids or purchases for the purpose of
pegging, fixing or maintaining the price of the shares, so long as stabilizing bids do
not exceed a specified maximum. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Over-allotments
and syndicate covering transactions</I> &#150;&nbsp;Underwriters may sell more shares of
our common stock than the number of shares that they have committed to purchase in any
underwritten offering. This over-allotment creates a short position for the underwriters.
This short position may involve either &#147;covered&#148; short sales or &#147;naked&#148; short
sales. Covered short sales are short sales made in an amount not greater than the
underwriters&#146; over-allotment option to purchase additional shares in any
underwritten offering. The underwriters may close out any covered short position either
by exercising their over-allotment option or by purchasing shares in the open market. To
determine how they will close the covered short position, the underwriters will consider,
among other things, the price of shares available for purchase in the open market, as
compared to the price at which they may purchase shares through the over-allotment
option. Naked short sales are short sales in excess of the over-allotment option. The
underwriters must close out any naked position by purchasing shares in the open market. A
naked short position is more likely to be created if the underwriters are concerned that,
in the open market after pricing, there may be downward pressure on the price of the
shares that could adversely affect investors who purchase shares in the offering. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Penalty
bids</I> &#150;&nbsp;If underwriters purchase shares in the open market in a stabilizing
transaction or syndicate covering transaction, they may reclaim a selling concession from
other underwriters and selling group members who sold those shares as part of the
offering. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Similar to other purchase
transactions, an underwriter&#146;s purchases to cover the syndicate short sales or to
stabilize the market price of our common stock may have the effect of raising or
maintaining the market price of our common stock or preventing or mitigating a decline in
the market price of our common stock. As a result, the price of the shares of our common
stock may be higher than the price that might otherwise exist in the open market. The
imposition of a penalty bid might also have an effect on the price of shares if it
discourages resales of the shares.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>If commenced, the underwriters may
discontinue any of these activities at any time.  </FONT></P>

<p align=center>
<font size=2>7</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our common stock is traded on the
NASDAQ Capital Market. One or more underwriters may make a market in our common stock,
but the underwriters will not be obligated to do so and may discontinue market making at
any time without notice. We cannot give any assurance as to liquidity of the trading
market for our common stock.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Any underwriters who are qualified
market makers on the NASDAQ Capital Market may engage in passive market making
transactions in the common stock in accordance with Rule&nbsp;103 of Regulation&nbsp;M,
during the business day prior to the pricing of the offering, before the commencement of
offers or sales of the common stock. Passive market makers must comply with applicable
volume and price limitations and must be identified as passive market makers. In general,
a passive market maker must display its bid at a price not in excess of the highest
independent bid for such security; if all independent bids are lowered below the passive
market maker&#146;s bid, however, the passive market maker&#146;s bid must then be
lowered when certain purchase limits are exceeded.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>In compliance with guidelines of the
Financial Industry Regulatory Authority, or FINRA, the maximum commission or discount to
be received by any FINRA member or independent broker dealer may not exceed 8% of the
aggregate amount of the securities offered pursuant to this prospectus and any applicable
prospectus supplement.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>VALIDITY OF SECURITIES </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The validity of the securities
offered hereby will be passed upon for us by Zysman, Aharoni, Gayer &amp; Co. /Sullivan
&amp; Worcester, LLP, Boston, Massachusetts.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXPERTS </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The financial statements of
Pluristem Therapeutics Inc. appearing in its Annual Report (Form&nbsp;10-KSB) for the
year ended June 30, 2007 have been audited by Kost Forer Gabbay &amp; Kasierer A member
of Ernst &amp; Young Global, independent registered public accounting firm, as set forth
in their report thereon, included therein, and incorporated herein by reference. Such
financial statements are incorporated herein by reference in reliance upon such report
given on the authority of such firm as experts in accounting and auditing.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>WHERE YOU CAN FIND MORE
INFORMATION </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We file reports, proxy statements
and other documents with the Securities and Exchange Commission. You may read and copy
any document we file with the SEC at the SEC&#146;s Public Reference Room at 100&nbsp;F&nbsp;Street,
N.E., Room&nbsp;1580, Washington,&nbsp;D.C. 20549. Please call the SEC at 1-800-SEC-0330
for further information on the public reference room.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The SEC also maintains a website,
the address of which is www.sec.gov. That site also contains our annual, quarterly and
current reports, proxy statements, information statements and other information.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We have filed this prospectus with
the SEC as part of a registration statement on Form&nbsp;S-3 under the Securities Act.
This prospectus does not contain all of the information set forth in the registration
statement because some parts of the registration statement are omitted in accordance with
the rules and regulations of the SEC. You can obtain a copy of the registration statement
from the SEC at the address listed above or from the SEC&#146;s website.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We also maintain a website at
www.pluristem.com, through which you can access our SEC filings. The information set
forth on our website is not part of this prospectus.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>INCORPORATION OF
DOCUMENTS BY REFERENCE </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We are &#147;incorporating by
reference&#148; certain documents we file with the SEC, which means that we can disclose
important information to you by referring you to those documents. The information in the
documents incorporated by reference is considered to be part of this prospectus.
Statements contained in documents that we file with the SEC and that are incorporated by
reference in this prospectus will automatically update and supersede information
contained in this prospectus, including information in previously filed documents or
reports that have been incorporated by reference in this prospectus, to the extent the
new information differs from or is inconsistent with the old information.  </FONT></P>

<p align=center>
<font size=2>8</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We have filed or may file the
following documents with the SEC. These documents are incorporated herein by reference as
of their respective dates of filing:  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Annual Report on Form 10-KSB for the year ended June 30, 2007;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Quarterly Report on Form 10-QSB for the quarter ended March 31, 2008;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Quarterly Report on Form 10-QSB for the quarter ended September 30, 2007;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Current Report on Form 8-K, as filed with the SEC on April 10, 2008;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Current Report on Form 8-K, as filed with the SEC on December 7, 2007;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Current Report on Form 8-K, as filed with the SEC on November 26, 2007;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Current Report on Form 8-K, as filed with the SEC on November 9, 2007;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Current Report on Form 8-K, as filed with the SEC on November 6, 2007;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Current Report on Form 8-K, as filed with the SEC on October 12, 2007;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Our
Current Report on Form 8-K, as filed with the SEC on September 5, 2007 ;</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The
description of our common stock contained in our Registration Statement on Form 8-A filed
with the               SEC, as amended; and</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=5%><FONT FACE="Wingdings 2" SIZE="1">&#154;</FONT></TD>
<TD WIDTH=90%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>All
documents filed by us pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange
Act (1)&nbsp;after the date of the filing of this registration statement and prior to its
effectiveness and (2)&nbsp;until all of the common stock to which this prospectus relates
has been sold or the offering is otherwise terminated, except in each case for
information contained in any such filing where we indicate that such information is being
furnished and is not to be considered &#147;filed&#148; under the Exchange Act, will be
deemed to be incorporated by reference in this prospectus and the accompanying prospectus
supplement and to be a part hereof from the date of filing of such documents. </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>We will provide a copy of the
documents we incorporate by reference, at no cost, to any person who receives this
prospectus. To request a copy of any or all of these documents, you should write or
telephone us at MATAM Advanced Technology Park, Building No. 20, Haifa, 31905, Israel,
Attention: Yaky Yanay, (+972) 74 710 7171.  </FONT></P>

<p align=center>
<font size=2>9</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px"><HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>pluristem.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pluristem.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!A`)H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WVBBF22)#
M&TDC!$499F.`!0`^N;U?QEIVF,T,1-U<#@I&?E4^[=*YCQ'XOFU)GM;!VBL^
MA<<-+_@/YURP&!@=*\/%YMRODH??_D>]@\HNN>O]W^9T%]XTUF\)$<RVJ'HL
M*\_F:QIKV[N&S/=SR$_WI":@HKQ:F(JU'><FSVZ="E35H12`$@Y#$'U!P:N6
M^KZG:8^SZA<H!V\PD?D<U3HK.,Y1UB[%RA&2M)7.MT_Q]?0$+?PI<IW9/D<?
MT/Z5VNE:Y8:Q'NM)@6'WHVX=?J*\=I\,TMO,LT$C1RH<JZ'!%>EA\UK4W:?O
M+\3S<3E5&JKP]U_A]Q[C17)^&/%JZF5LKXJEYCY6'"R_X'VKK*^CHUH5H<\'
MH?-UZ$Z$^2:U"BBBM3$****`"BBB@`HHHH`*\Y\:^(&N[EM+MGQ;Q']\1_&W
MI]!_.NO\2:I_9&BS7"$"9OW<7^\?\.OX5Y%SG)))/))[FO%S;%."5&/7?T/<
MR?"*3=:73;U"BBBOG3Z(****`"BBB@`HHI"<#-`&CHNE7&L:G';VS%-I#O*/
M^68'?Z^E>PHNR-5+%MH`W'J?<UB>%-'&DZ,F]<7,^))3W&>@_`5O5]9EV%]A
M2N]WN?)9EB_;U;1^&.P4445Z!YP4444`%%%%`!1110!Y_P"/[EI]1L-/5@`!
MO/\`O,=H_K5?_A7VIYYN[0#UPU0>)6\[QR%/020K_*MOQS;7M[/8P64,TKJK
MNRQ'G&5&>M?/SA3JSJU9QYFFDE^!]'3G4I0HTJ<E'F3;;^\P=1\%ZII]J]SN
MAN$0;F$6=P'K@]:K:3X9N]9L9+N">!(T8J0^<\`'M]:[/08KG1/"L[ZNY4#>
M^R1LE5QP,^_I[U5\%_)X1O'QC]Y*1[?**%@:+J1T:NFVNP/'5E3FTT[-).VC
M//:*Z;P=H%CK=K=27JR'RF4+L<KU&37-N!YSJOW?,*K],X%>54P\H0C4>TMC
MU85XSJ2IK>-K_,;174^+]`L-$L+>6T$@EE<J=[EN`I-:TO@_1(M.AO)YI+>(
M*LDS-(<$8Z#TYKH675>>4-+JWXG.\QHJ$9ZVE>VG8Y+0--CU?68;.60QQL&9
MBO4X'05O7GA:UL_%>EVEN[O!.3(Z.<LH3D\^AJ&WL-$U#Q99VVF/)]D,3,[(
M[*P<9Q@GD=JM2&+0_%]]<(9I_LE@9/WLA=B3CN>U=-&A"-/WTG[VZ?S.>M7G
M*I[C:]U^ZU\E^)Z`*:SJBEG8*H&22<`5P.FZIXNUQ9;BRFM4C1MN&4`9]!U-
M7_$,^NIX6C,T4&YHF6_/'RCI\M>NL;&5-U(Q=DK[;GC/`2C45.4E=NV^QU-M
M>6UXK-;3QS*K;6*-D`^E6*\Y\(/KL=NBZ=#`U@;C]ZSXW#INQSZ5L:UXFOCK
M`T;1(D>YSM>1QD`XSC'L.I-*GCHNDJDTU?\`'T'5R^2K.G!IV\]EY]CKJ*X:
M_P!5\4>'3#<:@]K=VSMM(C7;@^F>QK0\2>(I[/1+&_TUT`N7&"Z[OE*D_G5_
M7::4G)-..ZZD?4:CE%1::ELUL=317`MKOBF]TL7]G!'':Q)^\D*@M(1]Y@#V
MSFBP\5Z[JUL+.QM8I+\'+SD80)V./7-0LPI72L]=M-_0MY;5LW=:;Z[>IWU%
M<'I'B?68?$,>EZLJ.7D\L@*%*$C@Y'!%=Y6]#$0KIN/334Y\1AIX>24NNJL>
M9ZW$3\0T3^_-"1^E:7C;4+K3M8L9K28Q2^0XR`#P2.Q^E1>-!)IOB+3]5B16
M.WC=T+*>,_@?TKG-:URYUR>*:YCB1HE*@1YP03GO7A8BJJ/M:=[2;NOS/?P]
M)UO8U+7BHV?Y$-]JVH:EC[9=R2J#D*3A0?H.*[7PP?*\!W;G_IN?TKSZMFU\
M37EIHC:5'#`8&5E+D'=\V<]\=ZYL'B5"I*=1]&=.,PSJ4HTZ26C3['3?#R/&
MBWA7[S2X_)17'V.DWMUJT5I]FE63S1YFY"`H!Y)/I4FBZ]>:%(YMMCQR8WQR
M="1W]C6K>^.]3NHO+BBAMQD$E"68^V>U:^VP]2C!5&TX]+;F7LL33KU)4TFI
M6UOL:/Q(/[C3T'=G_D!4WCAFC\-V$/9I$!'T4FN5UKQ!=:Z8#<Q0IY))7RP>
M<XZY/M3]8\1W>MVT,%Q#"BQ-N4Q@Y/&.<FKK8RE)U6G\25C.C@ZL8T5)?"W?
MY[%GP0N?%,)](I#^@K>#Q-\2KN"<*8YK7RR&Z'@<5Q^D:O/HMX;JWCC>0H4Q
M)G`!(]/I27E__:NL?;+T!!*RB3RN,`<9&:RHXJ%.A&&[4KFU;"SJ5Y3>B<;?
M.YT.JV5UX*OX[W3+C-K.VWR)#GIS@^H]^HK>\0WR7W@::[0%5N(D(![9(XJF
MG@33_,5[G4KB:,C(5G`R/KZ?2NEN=-M+W2FT]DQ;,@0!#C:!TQ]*]:E0JJ-2
M*7*FM%>^IY-;$47*G)OFE%ZNUKK_`#,/P$R#PX1N&?M#Y&??BN7LX(SXVN;>
M^N9;<O+(/,CDV-N)R!GW%=/IW@:UT_4(;O[;<2>4^]4(`!(Z9QUJ_K/A;3]:
MD\Z8/%<8V^;&1DCW!X-0\+6G1@G%7ATON6L70A7FU)VFM[;?YE>Y\(Z?-%MN
MK[4'C!SB2YR![\BL3QO:PZ;H.EV5N6\J-V"[CDX"G_&M"+P%;B1#/J5Y,BD$
M(6&.#FM?7/#]IKJ0+=2RQB(G;Y9`SGZCVK2IAY3I32IJ+?F9T\3"G6@Y5'**
MN]K="&%5M_!`4#`6P/\`Z!6)\.(P+:_DQR71?PQ_]>NLDT^*323IQ9Q$8O*W
M#[V,8JMHFA6VA0S16TDCB1@S>802#C'85JZ$_;4Y=(JQBL1#V%2'63O^)R$R
M^=\4$']V93^25Z+6&GABT37SK'G3F<N7VDC;DC'I6Y582C.GSN75MD8RO"KR
M*'2*7S,'Q;I9U/0I1&NZ>`^;&/7'4?B,UY0#D9KW6O+O%^@MI5^;J%/]#N&R
M,=(W/5?QZBO/S?"MVK1^9Z.3XI*]"7JO\CG****^?/H`HHHH`****`"@C(HH
MH`[G0+V/6=/LK2>%);JSG0,64,3#S@_3H#^%:0MM2L[%/LC7"M(92Z;<B-=_
M&%['!.*\[LKV?3;R.\MGVRQG(]".X/L:]CT^YDO+""XE@:"21`S1MU6OH<OF
ML1%INTEU/GLQ@\/)2BKQ;V\S"0:BJ3.TUY,BJHCVJT?5CDG(+'`Q[U%#<:B[
MR1&2\,Z*#``A"DEVQOR.F`/O=O>NLI@1`[.%`=@`6QR<=*]'ZL]+2/-^M+6\
M3G+:35(YDFN9KA@LG[^)8&X&3T/<=/N_6H7_`+1FG>=([OS6<-"DB'8`&?&0
M1@?P_G7644?5M+<S#ZUK?E1ST3S_`&JS\N34)$+8E65&7GUSC&!W'OQ2/;WC
MZA?,K74,>'D7R^`[`*%^O0\5T5%5]7TLV3]8L[I&+I\TXFW7AO/M#-M*>6?*
M`/0C`QT_K6U116L(<JM>YC4FIN]K!4%W:07UK);7,8DBD&&4U/15-)JS)3:=
MT>3>(/#=SH<Q<!I;)C\DV/N^S>A]ZQ*]Q=$E1DD4,C##*PR"*X[5_`4$Y:72
MY!;N>?)?E#].XKP,7E,D^:AMV/H<'F\6N2OH^_\`F>?T5HWV@ZKIQ/VFRE"C
M^-!O7\Q6;N`."<'T/6O&G3G!VDK'M0G&:O%W0M%&1ZTL:M*VV)6D;T12Q_2H
M2;V*$H]!W/``[UNZ?X/UB_(+0?98S_'/P?P7K_*NXT3PI8:.5EP9[H?\M9!T
M_P!T=J]##Y;6K.[5EYG!B<RH45H[OLC$\+>$&5TU#5(\$?-%;MV/]YO\*[JB
MBOI</AX4(<D#YC$XFIB)\\_^&"BBBMSG"BBB@`HHHH`****`"BBB@`HHHH`#
MT->?^*O]:_X445Y^8_PCT<L_C')P?Z_\:],\,_\`'O117F95_$/4S?\`A'04
<445]&?-!1110`4444`%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
